maintenance after tirzepatide for the of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN Tirzepatide Dosing - A Patient
Description
Efsitora showed rates of 0.47, 0.65, and 0.50, and degludec showed rates of 0.47, 0.30, and 0.37 events per participant per year for Days 0, 3, and 6, respectively
Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, Von Eynatten M
Despite this, Cipro is still widely prescribed, leading to ongoing risks
And the company has made it clear: It doesn't sell semaglutide for compounding
[DOI] [PMC free article] [PubMed] [Google Scholar] 204.Pierret ACS, et al
Pham and Chilton, 2017)
